<DOC>
	<DOCNO>NCT00146471</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety levetiracetam treat alcohol withdrawal syndrome ( AWS ) inpatient ( vs. placebo ) . The primary come-out parameter reduction total need amount diazepam add-on treatment acute alcohol withdrawal symptom . The secondary come-out parameter - safety criterion ( AE ) - reduction alcohol withdrawal score day .</brief_summary>
	<brief_title>Efficacy Safety Levetiracetam Inpatient Treatment Alcohol Withdrawal Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Substance Withdrawal Syndrome</mesh_term>
	<mesh_term>Ethanol</mesh_term>
	<mesh_term>Diazepam</mesh_term>
	<mesh_term>Etiracetam</mesh_term>
	<mesh_term>Piracetam</mesh_term>
	<criteria>Ages eligible study : 1865 year . Meets criteria alcohol dependence accord DSMIV/ICD10 Known withdrawal symptom past case discontinuation alcohol consumption Hospital admission alcohol detoxification Able provide write informed consent . Able follow verbal write instruction ( incl . sufficient knowledge German language ) . Must medically acceptable study treatment . No past present physical disorder likely deteriorate participation . No ECG abnormality would likely worsen participation clinical laboratory abnormality would also suggest deterioration treatment . Have negative urine drug screen benzodiazepine heroine methadone Current diagnosis substance dependence syndrome alcohol dependence ( exclude nicotine caffeine dependence ) . History idiopathic epilepsy . Patient current clinically significant psychiatric disorder ( acute suiciality ) developmental disorder ( include organic mental disorder ) , like psychotic disorder . Patients follow complication alcoholism ( lifetime ) : acute delirium tremens , hallucinatory alcoholic state , Korsakoff ` syndrome , Wernicke encephalopathy , decompose liver cirrhosis ( Child B , C ) , suspect cirrhosis follow clinical symptom detect clinical exam : sign portal hypertension sign hepatocellular failure , thrombocytopenia . Subjects know sensitivity previous adverse reaction levetiracetam Contraindication ( hypersensitivity levetiracetam pyrrolidone derivative ) know nonresponse levetiracetam . History severe GI disease might render absorption medication difficult produce medical instability patient would include active peptic ulcer disease , ulcerative colitis , regional colitis , evidence history physical exam GI bleeding . Patients clinically significant acute chronic progressive neurological , gastrointestinal , cardiovascular , hepatic , renal , haematological , endocrine , dermatological respiratory disease , diabetes , severe infection , acute alcoholic hepatitis , medical condition significant worsen clinical situation patient might interfere evaluation study medication . Female patient pregnant , breastfeed child bearing age protect effective contraceptive implant , injectables , combine oral contraceptive , IUDS , sexual abstinence , sterilization vasectomize partner . Actually continuous use pharmacological agent know low seizure threshold augment decrease alcohol withdrawal syndrome . Subjects know sensitivity previous adverse reaction diazepam clonidine Contraindication know nonresponse diazepam clonidine</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2008</verification_date>
	<keyword>alcohol withdrawal</keyword>
	<keyword>detoxification</keyword>
	<keyword>Inpatients</keyword>
	<keyword>alcohol dependence accord DSM-IV/ICD-10</keyword>
	<keyword>withdrawal symptom</keyword>
</DOC>